Excigen

Excigen is a preclinical-stage biotechnology company headquartered in Baltimore, Maryland, specializing in the development of next-generation adeno-associated virus (AAV) gene therapies. The company focuses on addressing prevalent ocular conditions, with a primary emphasis on treating wet age-related macular degeneration (wet AMD) through its lead program, EXG-001. Excigen utilizes a proprietary AAV vector platform designed to enhance delivery efficiency and therapeutic durability while enabling less invasive administration routes. Founded by experts in viral vector engineering, the company's technology aims to provide long-lasting therapeutic effects for patients with vision-threatening diseases. Excigen's foundational research is closely integrated with the broader development efforts of its strategic partner, Exegenesis Bio.